US FDA Approves Pfizer’s CIBINQO^® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis

Pfizer, Inc. announced that the US FDA approved CIBINQO® (abrocitinib), an oral, once-daily, Janus kinase 1 inhibitor, for the treatment of adults living with refractory, moderate-to-severe atopic dermatitis.